• Queue

  Participated · Seed · Jun 2026

  Queue has developed a fully autonomous robotic pharmacy system that takes sealed wholesale pill bottles in one end and produces filled, verified prescription vials out the other. The platform currently supports 250 of the most prescribed medications in the United States and the company says it can deliver medications at up to 96% lower cost than traditional pharmacy operations. Queue has deployed a working prototype and has secured a major national pharmacy chain as a customer, providing early commercial validation. The company was co-founded by CEO Nick Desai and CTO Josh Liu; Desai previously founded Heal and Liu’s experience includes roles at Tesla and Zipline. Queue currently has a team of 20 engineers in Silicon Valley and is actively hiring across robotics, hardware, software and pharmacy operations. The company is positioning its autonomous fulfillment system for deployment across retail locations, hospitals, rural communities and other care settings facing pharmacy access and labor challenges.

• A&K Robotics

  Participated · Series A · Apr 2026

  A&K Robotics develops Cruz™, a self-driving mobility pod powered by its Kinesos™ AI platform for socially intelligent autonomy that navigates dense, dynamic indoor environments. Cruz enables riders to select destinations while the pod uses onboard sensors and AI to move safely alongside pedestrians and arrive precisely at intended locations. The company already has deployments with airport operators including Vancouver International Airport (YVR) and Madrid-Barajas Airport (MAD). A&K works closely with leading operators to integrate autonomous mobility into everyday airport operations to improve accessibility and operational efficiency. Recent funding will support scaling from pilot programs to permanent deployments, expanding R&D and rapid prototyping capabilities, and increasing manufacturing capacity at a new Surrey facility from dozens to hundreds of vehicles per year. The company is based in Vancouver, British Columbia.

• Ensis

  Participated · Seed · Mar 2024

  Ensis develops an AI-powered proposal platform that leverages generative models to streamline creation of responses to government RFPs, RFIs and similar opportunities. The product trains a reference library for each client that is securely stored and siloed per company to capture unique capabilities and writing style. Clients can import new RFPs into the system, which parses, organizes, and drafts responses for each section within a single workflow. Ensis is currently running a private beta and plans a wide release in 2H 2024. The company intends to use the seed funding to expand operations and accelerate development efforts. Founders Ben Lewis and Jon Sockell are leading the product and go-to-market work from San Francisco.

• CHARM Therapeutics

  Participated · Series A · Jun 2022

  Charm Therapeutics develops precision oncology treatments via a proprietary AI-driven drug discovery platform. Its lead program is a menin inhibitor targeting acute myeloid leukemia (AML). The company's candidates are designed to retain potency against known clinical resistance mutations, aiming to deliver more durable patient responses. Charm was founded by Laksh Aithani and David Baker and is based in London and Cambridge, UK. Following its Series B, the company is advancing its programs toward clinical trials. The company raised $80M in Series B financing to support these efforts. CHARM Therapeutics is a London-based 3D deep-learning biotechnology company that discovers and develops small-molecule medicines for difficult-to-drug cancer targets using its proprietary DragonFold protein-ligand co-folding platform. The company applies high-throughput protein-ligand co-folding and machine learning to identify novel molecules and accelerate preclinical discovery. CHARM leverages accelerated computing, including NVIDIA GPUs, to rapidly identify potential compounds. The recent investment from NVentures will support R&D and help fund its rapidly growing organization as it advances novel oncology programs. CHARM has raised $70 million to date and is supported by investors such as OrbiMed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, and NVIDIA. The company plans to use the funding and NVIDIA's accelerated computing platform to bring potential new therapies to patients faster. Charm Therapeutics built DragonFold, which it describes as the first protein–ligand co‑folding algorithm for predicting how proteins and potential drugs interact. The company applies machine learning to simulate complex protein interactions and aims to screen vastly larger sets of candidate molecules while reducing wet‑lab screening. Early‑stage funding was used to build the initial model, which has been validated in‑silico. Over the coming quarters Charm plans to validate DragonFold experimentally and use the platform to discover medicines. The company intends the product primarily for internal use so its scientists can identify drug candidates that Charm owns 100% of the rights to. Leadership and technical credibility include co‑founder and CEO Laskh Aithani and co‑founder David Baker, with Sergey Bartunov as director of AI and Sarah Skerratt as head of drug discovery.

No current team members are available.